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SHORT COMMUNICATION
Tumour cell products inhibit both functional and immunoreactive
interleukin 2 production by human blood lymphocytes
M. Nelson, J.A.G. Bremner & D.S. Nelson
Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.
Many tumours that grow progressively do so despite the
ability of the host to offer defences in the form either of
natural immunity, e.g. natural killer cells, or of specifically
acquired immunity, e.g. cytotoxic T-cells or activated macro-
phages delivered by delayed-type hypersensitivity reactions
(Herberman & Ortaldo, 1981; Doherty et al., 1984; Robins
& Baldwin, 1985).
One of the ways in which tumours can resist the operation
of natural or acquired immune defences is by producing
factors that interfere with the operation of those defences.
We have examined many tumours, of different types and
species of origin, and have found that all produce factors
that depress the expression of cell-mediated immunity, in the
form of delayed-type hypersensitivity (DTH) reactions in
mice (Nelson et al., 1981; Nelson & Nelson, 1987). In vitro,
tumour culture supernatants inhibited the production of
interleukin 1 (ILl) by mouse macrophages and macrophage
chemotactic factor and interleukin 2 (IL2) by mouse spleen
cells (Farram et al., 1982; Nelson & Nelson, 1988). Hersey
et al. (1983) have also reported that some melanoma culture
supernatants inhibited the production of IL2 by human
blood lymphocytes.
Because IL2 is central to the expression of cell-mediated
immunity we have studied further the effects of tumour cell
culture supernatants on its production. Cells of the mouse
thymoma EL4, stimulated either by concanavalin A (ConA),
as concanavalin A-Sepharose (Pharmacia, Uppsala) or by
phorbol myristate acetate (PMA) and the calcium ionophore
A23187, produced 20-80% less IL2 in the presence of any of
a variety of tumour culture supernatants (Nelson et al.,
1988). As production in this system is independent of ILl, it
is thus clear that IL2 production can be inhibited indepen-
dently of any effect of tumour products on ILl production.
A similar conclusion was drawn by Hersey et al. (1983), who
could not, in fact, detect any inhibition of ILl production by
human blood monocytes in the presence of melanoma
supernatants. With EL4 cells, inhibition of IL2 production
was selective, in that it was inhibited to a greater degree than
was general protein synthesis in EL4 cells, and general
protein synthesis in fibroblasts was not inhibited.
A further important question, however, is whether IL2
production is truly inhibited, or whether tumour cell pro-
ducts stimulate the synthesis of an inhibitor of IL2 activity,
such as 'contra-IL2' (Maki et al., 1986). This can be
answered with reasonable certainty by comparing IL2
measured in a functional assay with IL2 measured in an
immunoassay. This is most readily done with human
lymphocytes, as immunoassays for human IL2 are available
commercially.
Mononuclear leukocytes were separated from the peri-
pheral blood of normal human donors by standard methods,
using Ficoll-Hypaque discontinuous gradient centrifugation.
They were cultured in serum-free RPMI 1640 medium
(Gibco, Grand Island, NY, USA) containing 28mM Hepes
buffer, penicillin (100 Uml-1), streptomycin (100 ugml-1),
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human transferrin (20pgml-1; Sigma, St Louis, MO, USA)
and pork insulin (0.5Uml-1; CSL, Melbourne, Australia).
Cultures, in Linbro 24-well plates, contained 0.5ml of
mononuclear cells (4x 106ml-1) and 0.5ml of tumour or
fibroblast supernatant or control medium. The cells were
stimulated either with ConA at various concentrations or
with a mixture of PMA (Sigma) at a final concentration of
10ngml-1 and phytohaemagglutinin (Bacto PHA-P, Difco,
Detroit, MI) at a final concentration of 5 or 0lpgml-l.
After culture for 24h the supernatants were collected and
assayed for IL2, either immediately or after storage at
-70°C.
The mouse IL2-dependent T-cell line CTLL was used for
functional assays of IL2, essentially as described by Gillis et
al. (1978). The CTLL cells were maintained in Dulbecco's
modified Eagle's medium (DME, Gibco), with 10% heated
(56°C, 30min) fetal calf serum (FCS, Flow Laboratories,
Sydney), 5 x 10-5M 2-mercaptoethanol, glucose (4mgml-1)
and IL2 (20-30Uml- ). The IL2 was either purified human
rIL2 (Boehringer Mannheim, FR Germany) or a crude
preparation containing mouse IL2, from EL4 cells stimulated
with PMA (10ngml-1) and the ionophore A23187
(50ngml-1; Sigma). For assays of IL2, serial doubling
dilutions of the human lymphocyte culture supernatants were
made in RPMI 1640 (with transferrin and insulin). Thrice-
washed CTLL cells were suspended (1-2x 10 ml-1) in
RPMI 1640 medium containing 10-4M 2-mercaptoethanol,
glucose (8mgml-1) and 20% heated FCS. Triplicate 50pl1
samples of lymphocyte culture supernatants were mixed with
50l of CTLL suspension in the wells of flat-bottomed 96-
well plates (Linbro, Maclean, VA) and incubated for 24h.
Tritiated thymidine incorporation was measured over the last
4h. One unit of IL2 is defined as the amount required to
give half the maximal incorporation of tritiated thymidine.
The tumour cells used included two human melanoma
lines (IGR3, PMC 22/10), six human breast cancer lines
(MCF-7, A-431, MDA-MB-231, HBL-100, ZR-75-1,
T-47-D), HeLa cells, a spontaneous mouse sarcoma (SCS-3)
and a methylcholanthrene-induced mouse sarcoma (A-2).
Normal human fibroblasts were grown from a skin biopsy.
The cells were obtained from several sources (Garvan
Institute and Ludwig Institute, Sydney; CSL, Melbourne;
University of Adelaide; our own lines). They were main-
tained in RPMI 1640 with 10% heated FCS (human cells)
and additional insulin (0.5Uml-1, breast cancer lines) or
DME with 10% heated FCS (mouse lines). Supernatants were
obtained from confluent cultures that had been washed three
times with normal saline and cultured for 24h in RPMI 1640
only. The supernatants were passed through 0.2pm Millipore
filters before use.
Immunoassays of IL2 were carried out by ELISA, with a
kit (Intertest 2) from Genzyme (Boston, MA). The concen-
tration of IL2 is determined from a standard curve prepared
with a reference sample (supplied).
Lymphocytes from eight different donors produced IL2 in
response to Con A (6.25 or 12.5pgml-1), and their IL2
production was inhibited by 24-87% by tumour super-
natants (breast cancer and melanoma lines) at a final
concentration of 50%. Inhibition was dose dependent. The
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Figure 1 Relationship between inhibition of functional IL-2 and
inhibition of immunoreactive IL-2 by supernatants from different
tumours (circles). The black square shows the lack of inhibition
by a fibroblast supernatant. These results are plotted from two
experiments, in which the inhibition of IL2 production was
measured, by bioassay and immunoassay (ELISA), in super-
natants from mononuclear cells stimulated with PHA and PMA
in the presence or absence of 50% supernatants from cultures of
tumour cells or fibroblasts. The percentage inhibition of IL2
production was calculated, in each case as:
IL2 (Uml-1) in control-IL2 (Uml-1)
in 50% cell supernatant 100.
IL2 (Uml-') in control
In one experiment the supernatants added to blood mononuclear
cells came from the tumours A-2 (mouse sarcoma, point 3), SCS-
3 (mouse sarcoma, 4) and IGR3 (melanoma, 5). In the other
experiment the supernatants were from tumours HBL-100
(breast, 1), HeLa (2), MDA-MB-231 (breast, 6), MCF-7 (breast,
7), A-431 (breast, 8), PMC 22/10 (melanoma, 9) and fibroblasts.
amounts of IL2 produced were, however, too small to be
measured in the ELISA assay.
In two further experiments, lymphocytes stimulated with a
mixture of PMA and PHA produced enough IL2 for the
ELISA assay. Supernatants from nine tumour cell cultures
(four breast cancer, two melanoma, HeLa, and two mouse
sarcomas) all inhibited IL2 production, as measured in both
assays. Fibroblasts had no significant effect. Figure 1 shows
the degree of inhibition in the two assays, plotted against
each other. There is a high degree of correlation (r=0.90).
In a typical bioassay, tritiated thymidine uptake (d.p.m.)
by CTLL cells in the presence of serial doubling dilutions of
a lymphokine preparation (supernatant) from control stimu-
lated mononuclear cells was: 42,261 + 1,230; 35,207 +729;
15,549+470; 7,193 +320. By contrast, uptake by CTLL cells
in the presence of dilutions of a lymphokine from mono-
nuclear cells stimulated in the presence of 50% supernatant
from the melanoma line IGR3 was: 23,497+766; 9,273 + 179;
2,689+ 165; 1,183 +21. In the presence of dilutions of super-
natants from unstimulated mononuclear cells, uptake by
CTLL cells was: 459+25; 448+36; 370+22; 377+ 13. Maxi-
mum uptake of CTLL in the presence of excess recombinant
IL2 was 66,492 + 1,034d.p.m. Following calculation of these
results according to Gillis et al. (1978) the control lympho-
kine preparation contained 177.5 Um1-1 IL2, while that
prepared in the presence of IGR3 supernatant contained
44.1 Uml-1. The same preparations in the ELISA assay gave
OD readings of0.153 +0.090 and 0.068 +0.005, corresponding
to values of 7.49 and 2.63 U ml-, according to Genzyme
IL2 standard supplied.
None of the tumour supernatants inhibited the response of
the CTLL cells to exogenous recombinant IL2. Tritiated
thymidine incorporation by CTLL alone was 665 +23 d.p.m.
and in the presence of various cell supernatants without IL2
it was between 613+35 and 719+22. In the presence of 1 unit
of recombinant human IL2 it was 6,216+351 for the control,
and between 5,706+256 and 7,114+ 107 for CTLL cells in the
presence of tumour cell supernatants at the same concen-
trations as in the experiments above.
Thus, the apparent inhibition of IL2 production is due
neither to the production of a functional inhibitor of IL2 nor
to an inhibitor of DNA synthesis (Werkmeister et al., 1980).
It remains to be seen whether the inhibitory effect of tumour
products is exerted at a pre- or post-transcriptional level. It
is possible that inhibition of IL2 production is secondary,
wholly or in part, to inhibition of ILl production. Other
studies with mouse lymphoid cells indicate that inhibition of
IL2 production can occur independently of inhibition of ILl
production (Nelson et al., 1988). The chemical nature of the
inhibitor(s) is under study, particularly their relationship to
the retroviral envelope protein p15E. In studies with mouse
EL4 cells, synthetic peptides based on conserved regions of
pi5E have also inhibited IL2 production (Nelson et al.,
1988).
Inhibition of IL2 production would be a strategically very
effective way for tumours to evade or subvert some host
defences. This may account for the depressed capacity of
lymphocytes from some cancer patients to produce IL2
(Wanebo et al., 1986; Elliott et al., 1987). Perhaps more
importantly, they may be responsible for the lack of anti-
tumour effectiveness of tumour-associated lymphocytes
which, when isolated and cultured with IL2, can give rise to
potent lymphokine-activated killer (LAK) cells (Belldegrun et
al., 1988). The induction of resistance to such products (e.g.
by immunisation) might offer a novel approach to immuno-
logical intervention in cancer, and could perhaps obviate the
need for large and toxic doses of IL2 in immunotherapy
involving LAK cells (Rosenberg et al., 1987).
This work was supported by the New South Wales State Cancer
Council and Trust Funds of The Royal North Shore Hospital.
References
BELLDEGRUN, A., MULL, L.M. & ROSENBERG, S.A. (1988). Inter-
leukin 2 expanded tumor-infiltrating lymphocytes in human renal
cell cancer: isolation, characterization, and antitumor activity.
Cancer Res., 48, 206.
DOHERTY, P.C., KNOWLES, B.B. & WETTSTEIN, P.J. (1984).
Immunological surveillance of tumors in the context of major
histocompatibility complex restriction of T cell function. Adv.
Cancer Res., 42, 1.
ELLIOTT, L., BROOKS, W. & ROSZMAN, T. (1987). Role of inter-
leukin-2 (IL-2) and IL-2 receptor expression in the proliferative
defect observed in mitogen-stimulated lymphocytes from patients
with gliomas. J. Natl Cancer Inst., 78, 919.
FARRAM, E., NELSON, M. & NELSON, D.S. (1982). Inhibition of
cytokine production by a tumour cell product. Immunology, 46,
603.
GILLIS, S., FERM, M.M., OU, W. & SMITH, K.A. (1978). T cell growth
factor: parameters of production and a quantitative microassay
for activity. J. Immunol., 120, 2027.
HERBERMAN, R.B. & ORTALDO, J.R. (1981). Natural killer cells:
Their role in defenses against disease. Science, 214, 24.
HERSEY, P., BINDON, C., CZERNIECKI, M., SPURLING, A., WASS, J.
& McCARTHY. W.H. (1983). Inhibition of interleukin 2 produc-
tion by factors released from tumor cells. J. Immunol., 131,
2837.
MAKI, T., SATOMI, S., GOTOH, M. & MONACO, A.P. (1986). Contra-
IL2: a suppressor lymphokine that inhibits IL2 activity. J.
Immunol., 136, 3298.
NELSON, D.S. & NELSON, M. (1987). Evasion of host defences by
tumours. Immunol. Cell Biol., 65, 287.TUMOURS AND INTERLEUKIN 2 163
NELSON, D.S., NELSON, M., FARRAM, E. & INOUE, Y. (1981).
Cancer and subversion of host defences. Aust. J. Exp. Biol. Med.
Sci., 59, 229.
NELSON, D.S., NELSON, P., CIANCIOLO, G.J. & SNYDERMAN, R.
(1988). Tumour-induced immunosuppression: inhibition of inter-
leukin 2 production by tumour cell products and a pl5E-related
peptide. J. Leuk. Biol., 44, 270.
NELSON, M. & NELSON, D.S. (1988). Inhibition of cell-mediated
immunity by tumour cell products: depression of interleukin-2
production and responses to interleukin-2 by mouse spleen cells.
Immunol. Cell Biol., 66, 97.
ROBINS, R.A. & BALDWIN, R.W. (1985). T cell subsets in tumour
rejection. Immunol. Today, 6, 55.
ROSENBERG, S.A., LOTZE, M.T., MUUL, L.M. and 10 others (1987).
A progress report on the treatment of 157 patients with
advanced cancer using lymphokine-activated killer cells and
interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med.,
316, 889.
WANEBO, H.J., PACE, R., HARGETT, S., KATZ, D. & SANDO, J.
(1986). Production of and response to interleukin-2 in peripheral
blood lymphocytes of cancer patients. Cancer, 57, 656.
WERKMEISTER, J., ZAUNDERS, J., McCARTHY, W.H. & HERSEY, P.
(1980). Characterization of an inhibitor of cell division released
in tumour cell cultures. Clin. Exp. Immunol., 41, 487.